Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 3257 citing articles:

Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro, et al.
New England Journal of Medicine (2008) Vol. 359, Iss. 4, pp. 378-390
Open Access | Times Cited: 11931
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Peter R. Galle, Alejandro Forner, Josep M. Llovet, et al.
Journal of Hepatology (2018) Vol. 69, Iss. 1, pp. 182-236
Closed Access | Times Cited: 10108
Hepatocellular carcinoma
Alejandro Forner, María Reig, Jordi Bruix
The Lancet (2018) Vol. 391, Iss. 10127, pp. 1301-1314
Closed Access | Times Cited: 4613
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo, Richard S. Finn, Shukui Qin, et al.
The Lancet (2018) Vol. 391, Iss. 10126, pp. 1163-1173
Open Access | Times Cited: 4491
Hepatocellular carcinoma
Josep M. Llovet, Robin Kate Kelley, Augusto Villanueva, et al.
Nature Reviews Disease Primers (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 4472
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
Jorge A. Marrero, Laura Kulik, Claude B. Sirlin, et al.
Hepatology (2018) Vol. 68, Iss. 2, pp. 723-750
Open Access | Times Cited: 3872
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry, Bruno Sangro, Thomas Yau, et al.
The Lancet (2017) Vol. 389, Iss. 10088, pp. 2492-2502
Open Access | Times Cited: 3855
Hepatocellular Carcinoma
Augusto Villanueva
New England Journal of Medicine (2019) Vol. 380, Iss. 15, pp. 1450-1462
Closed Access | Times Cited: 3632
A global view of hepatocellular carcinoma: trends, risk, prevention and management
Ju Dong Yang, Pierre Hainaut, Gregory J. Gores, et al.
Nature Reviews Gastroenterology & Hepatology (2019) Vol. 16, Iss. 10, pp. 589-604
Open Access | Times Cited: 3437
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
María Reig, Alejandro Forner, Jordi Rimola, et al.
Journal of Hepatology (2021) Vol. 76, Iss. 3, pp. 681-693
Open Access | Times Cited: 2810
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu, Richard S. Finn, Julien Edeline, et al.
The Lancet Oncology (2018) Vol. 19, Iss. 7, pp. 940-952
Closed Access | Times Cited: 2235
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Ghassan K. Abou‐Alfa, Tim Meyer, Ann‐Lii Cheng, et al.
New England Journal of Medicine (2018) Vol. 379, Iss. 1, pp. 54-63
Open Access | Times Cited: 2027
Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
Masao Omata, Ann‐Lii Cheng, Norihiro Kokudo, et al.
Hepatology International (2017) Vol. 11, Iss. 4, pp. 317-370
Open Access | Times Cited: 1890
Molecular therapies and precision medicine for hepatocellular carcinoma
Josep M. Llovet, Robert Montal, Daniela Sia, et al.
Nature Reviews Clinical Oncology (2018) Vol. 15, Iss. 10, pp. 599-616
Open Access | Times Cited: 1632
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
Richard S. Finn, Baek‐Yeol Ryoo, Philippe Merle, et al.
Journal of Clinical Oncology (2019) Vol. 38, Iss. 3, pp. 193-202
Closed Access | Times Cited: 1551
Epidemiology and Management of Hepatocellular Carcinoma
Laura Kulik, Hashem B. El–Serag
Gastroenterology (2018) Vol. 156, Iss. 2, pp. 477-491.e1
Open Access | Times Cited: 1502
Tumor angiogenesis: causes, consequences, challenges and opportunities
Roberta Lugano, Mohanraj Ramachandran, Anna Dimberg
Cellular and Molecular Life Sciences (2019) Vol. 77, Iss. 9, pp. 1745-1770
Open Access | Times Cited: 1454
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu, Yoon‐Koo Kang, Chia‐Jui Yen, et al.
The Lancet Oncology (2019) Vol. 20, Iss. 2, pp. 282-296
Closed Access | Times Cited: 1436
Hepatocellular carcinoma
Arndt Vogel, Tim Meyer, Gonzalo Sapisochín, et al.
The Lancet (2022) Vol. 400, Iss. 10360, pp. 1345-1362
Closed Access | Times Cited: 1345
From NASH to HCC: current concepts and future challenges
Quentin M. Anstee, Helen L. Reeves, Elena Kotsiliti, et al.
Nature Reviews Gastroenterology & Hepatology (2019) Vol. 16, Iss. 7, pp. 411-428
Closed Access | Times Cited: 1147
Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis
Daniela Sia, Augusto Villanueva, Scott L. Friedman, et al.
Gastroenterology (2016) Vol. 152, Iss. 4, pp. 745-761
Open Access | Times Cited: 1009
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib
Thomas Yau, Yoon‐Koo Kang, Tae‐You Kim, et al.
JAMA Oncology (2020) Vol. 6, Iss. 11, pp. e204564-e204564
Open Access | Times Cited: 989
Advances in immunotherapy for hepatocellular carcinoma
Bruno Sangro, Pablo Sarobe, Sandra Hervás‐Stubbs, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 8, pp. 525-543
Open Access | Times Cited: 938
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Arndt Vogel, Andrés Cervantes, Ian Chau, et al.
Annals of Oncology (2018) Vol. 29, pp. iv238-iv255
Open Access | Times Cited: 882
Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
Daniela Sia, Yang Jiao, Iris Martinez-Quetglas, et al.
Gastroenterology (2017) Vol. 153, Iss. 3, pp. 812-826
Open Access | Times Cited: 761
Page 1 - Next Page

Scroll to top